Assessing the Economic Benefits of Enhanced Recovery After Surgery (ERAS) Protocols in Adult Cervical Deformity Patients: Is the Initial Additive Cost of Protocols Offset by Clinical Gains?

• Published in: Clinical spine surgery
• Main Authors: Tretiakov, Peter S, Onafowokan, Oluwatobi O, Lorentz, Nathan, Galetta, Matthew, Mir, Jamshaid M, Das, Ankita, Dave, Pooja, Yee, Timothy, Buell, Thomas J, Jankowski, Pawel P, Eastlack, Robert, Hockley, Aaron, Schoenfeld, Andrew J, Passias, Peter G
• Format: Journal Article
• Language: English
• Published: United States 01.05.2024
• DOI: 10.1097/BSD.0000000000001625

To assess the financial impact of Enhanced Recovery After Surgery (ERAS) protocols and cost-effectiveness in cervical deformity corrective surgery. Retrospective review of prospective CD database. Enhanced Recovery After Surgery (ERAS) can help accelerate patient recovery and assist hospitals in maximizing the incentives of bundled payment models while maintaining high-quality patient care. However, the economic benefit of ERAS protocols, nor the heterogeneous components that make up such protocols, has not been established. Operative CD patients ≥18 y with complete pre-(BL) and up to 2-year(2Y) postop radiographic/HRQL data were stratified by enrollment in Standard-of-Care ERAS beginning in 2020. Differences in demographics, clinical outcomes, radiographic alignment targets, perioperative factors, and complication rates were assessed through means comparison analysis. Costs were calculated using PearlDiver database estimates from Medicare pay scales. QALY was calculated using NDI mapped to SF6D using validated methodology with a 3% discount rate to account for a residual decline in life expectancy. In all, 127 patients were included (59.07±11.16 y, 54% female, 29.08±6.43 kg/m2) in the analysis. Of these patients, 54 (20.0%) received the ERAS protocol. Per cost analysis, ERAS+ patients reported a lower mean total 2Y cost of 35049 USD compared with ERAS- patients at 37553 (P<0.001). Furthermore, ERAS+ patients demonstrated lower cost of reoperation by 2Y (P<0.001). Controlling for age, surgical invasiveness, and deformity per BL TS-CL, ERAS+ patients below 70 years old were significantly more likely to achieve a cost-effective outcome by 2Y compared with their ERAS- counterparts (OR: 1.011 [1.001-1.999, P=0.048]. Patients undergoing ERAS protocols experience improved cost-effectiveness and reduced total cost by 2Y post-operatively. Due to the potential economic benefit of ERAS for patients incorporation of ERAS into practice for eligible patients should be considered.